Emergence of pristinamycin resistance in India

被引：6

作者：

Keshari, Shyam Sunder

Kapoor, Arun Kumar

Kastury, Nira

Singh, Dharmendra Kumar ^{[2
]}

Bhargava, Anudita ^{[1
]}

机构：

[1] Moti Lal Nehru Med Coll, Dept Pharmacol & Microbiol, Allahabad, Uttar Pradesh, India

[2] Sarojini Naidu Children Hosp, Dept Pediat, Allahabad, Uttar Pradesh, India

来源：

INDIAN JOURNAL OF PHARMACOLOGY | 2009年 / 41卷 / 01期

关键词：

Dalfopristin; quinupristin; pristinamycin resistance; staphylococcus; STAPHYLOCOCCUS-AUREUS; QUINUPRISTIN-DALFOPRISTIN; STREPTOGRAMIN-A; ANTIBIOTICS; GENES;

D O I：

10.4103/0253-7613.48884

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 g and 25 g, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.

引用

页码：47 / 48

页数：2

共 12 条

[1] In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method [J].